Ferris RL et al. Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: The phase III XRay Vision study design. Future Oncol 2024;20(12):739-48. Abstract

Khan SR et al. Mean level of pretreatment neutrophil to lymphocyte ratio in patients with squamous cell carcinoma of the head and neck-cross-sectional study. Heliyon 2023;9(5):e15894. Abstract

Lu D et al. PD-1 N58-glycosylation-dependent binding of monoclonal antibody cemiplimab for immune checkpoint therapy. Front Immunol 2022;13:826045. Abstract

Mai H-Q et al. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). ASCO 2023;Abstract 6009.

Mai H-Q et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: The JUPITER-02 randomized clinical trial. JAMA 2023;330(20):1961-70. Abstract

Tao Y et al. Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: A randomised clinical trial. Eur J Cancer 2023;183:24-37. Abstract

Tao Y et al. Long-term results from a clinical study of xevinapant plus chemoradiotherapy in people with high-risk locally advanced squamous cell carcinoma of the head and neck: A plain language summary. Future Oncol 2023;19(26):1769-76. Abstract

Zhang L et al. Toripalimab: The first domestic anti-tumor PD-1 antibody in China. Front Immunol 2022;12:730666. Abstract